Christian Schweiger
Oprichter bij SHIELD THERAPEUTICS PLC
Vermogen: 196 914 $ op 30-04-2024
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Hans-Peter Hasler | M | 68 | 6 jaar | |
| Karl Lundström | M | 62 | 3 jaar | |
| Jonas Hallén | M | - |
Arxx Therapeutics AS
 Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | 5 jaar |
| Jörg Klingelhöfer | M | - |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | 6 jaar |
| Lucy Huntington-Bailey | F | - | 9 jaar | |
| David Childs | M | - | 13 jaar | |
| Paul Spoors | M | - | 5 jaar | |
| Gregory Madison | M | 57 | 3 jaar | |
| Jackie Mitchell | M | - | 12 jaar | |
| Annette Koehler | M | 57 |
University of Duisburg-Essen
| 19 jaar |
| Peter Llewellyn-Davies | M | 66 | 8 jaar | |
| Maria Lacerca-Allen | M | 57 | 3 jaar | |
| Susanne Stuffers | M | 43 |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | - |
| Santosh Shanbhag | M | 47 | - | |
| Karen Chandler Smith | F | - | - | |
| Birgitte Gangmark Villmo | F | - |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | - |
| Volker Gruhn | M | 61 |
University of Duisburg-Essen
| - |
| Andy Hurley | M | - | 1 jaar | |
| Kari Grønås | F | 59 |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | - |
| Dieter Schmitt | M | - |
University of Duisburg-Essen
| - |
| Joachim Wuermeling | M | 63 |
University of Duisburg-Essen
| 28 jaar |
| Till Neumann | M | - |
University of Duisburg-Essen
| - |
| Øystein Soug | M | 55 |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | 2 jaar |
| Robert Huber | M | 87 |
University of Duisburg-Essen
| - |
| Yuri Khodjamirian | M | - |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | - |
| Tobias Kollmann | M | 54 |
University of Duisburg-Essen
| - |
| Bedrich Hosticka | M | - |
University of Duisburg-Essen
| 39 jaar |
| Farzad Abdi-Dezfuli | M | - |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| James Karis | M | 76 | 4 jaar | |
| Tim Watts | M | 66 | 3 jaar | |
| Carl Sterritt | M | 55 | 12 jaar | |
| Richard Jones | M | 58 | 7 jaar | |
| Joanne Elizabeth Estell | F | 53 | - | |
| Angela Hildreth | F | - | 6 jaar | |
| Rolf K. Hoffmann | M | 64 | 3 jaar | |
| Karl Keegan | M | 57 | 1 jaar | |
| Andrew Heath | M | 76 | 2 jaar | |
| Jose Menoyo | M | - | 2 jaar | |
| Mark Sampson | M | - | 5 jaar | |
| Karen Nugent | F | - | - | |
| Paul Steckler | M | - | - | |
| Kate Hopkinson | F | - | - | |
| Suzanne Wood | F | - | - | |
| Hans-Peter Rudolf | M | 58 | 2 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigd Koninkrijk | 28 | 63.64% |
| Noorwegen | 8 | 18.18% |
| Duitsland | 8 | 18.18% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Christian Schweiger
- Persoonlijk netwerk
